NASDAQ: ETON
Eton Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ETON stock forecasts and price targets.

Forecast return on equity

Is ETON forecast to generate an efficient return?

Company
N/A
Industry
36.28%
Market
238.59%

Forecast return on assets

Is ETON forecast to generate an efficient return on assets?

Company
N/A
Industry
19.01%

ETON earnings per share forecast

What is ETON's earnings per share in the next 2 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.92
Avg 2 year Forecast
$1.53

ETON revenue forecast

What is ETON's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$104.9M+47.41%
Avg 2 year Forecast
$140.9M+98.03%
Avg 3 year Forecast
$200.2M+181.38%
ETON's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ETON revenue growth forecast

How is ETON forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
41.18%
Industry
35.65%
Market
23.42%
ETON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ETON's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ETON vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ETON$16.05N/AN/A
CGC$1.07N/AN/A
AQST$3.82$9.33+144.32%Strong Buy
SIGA$6.64N/AN/A
ORGO$3.76$9.00+139.36%Strong Buy

Eton Pharmaceuticals Stock Forecast FAQ

What is ETON's earnings growth forecast for 2026-2027?

(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 51.42%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.

Eton Pharmaceuticals's earnings in 2026 is -$6,682,000.On average, 5 Wall Street analysts forecast ETON's earnings for 2026 to be $24,709,677, with the lowest ETON earnings forecast at $17,871,205, and the highest ETON earnings forecast at $32,945,342.

In 2027, ETON is forecast to generate $40,939,649 in earnings, with the lowest earnings forecast at $29,434,926 and the highest earnings forecast at $53,500,982.

If you're new to stock investing, here's how to buy Eton Pharmaceuticals stock.

What is ETON's revenue growth forecast for 2026-2028?

(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 41.18% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.42%.

Eton Pharmaceuticals's revenue in 2026 is $71,141,000.On average, 5 Wall Street analysts forecast ETON's revenue for 2026 to be $2,812,354,895, with the lowest ETON revenue forecast at $2,657,027,733, and the highest ETON revenue forecast at $2,988,009,750. On average, 5 Wall Street analysts forecast ETON's revenue for 2027 to be $3,778,054,331, with the lowest ETON revenue forecast at $3,316,792,729, and the highest ETON revenue forecast at $4,258,892,733.

In 2028, ETON is forecast to generate $5,368,334,156 in revenue, with the lowest revenue forecast at $4,179,244,654 and the highest revenue forecast at $6,574,318,705.

What is ETON's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: ETON) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 19.01%.

What is ETON's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: ETON) Eton Pharmaceuticals's current Earnings Per Share (EPS) is -$0.26. On average, analysts forecast that ETON's EPS will be $0.92 for 2026, with the lowest EPS forecast at $0.67, and the highest EPS forecast at $1.23. In 2027, ETON's EPS is forecast to hit $1.53 (min: $1.10, max: $2.00).

What is ETON's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: ETON) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.